Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | SI | P14410 | 1/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472723 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL1903946 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138462 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138705 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138882 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL3777425 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138788 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL3442509 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138989 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138757 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361801-B1 | AUTOINDUCER COMPOUNDS AND THEIR USES | PATHWAY INTERMEDIATES LTD (GB) | 2007-06-06 | — | — | EP | claimed |
| US-20040115245-A1 | Autoinducer compounds and their uses | GORMAR MARKETING LIMITED (KY) | 2004-06-17 | — | — | US | claimed |
| EP-1361801-A1 | AUTOINDUCER COMPOUNDS AND THEIR USES | Gormar Marketing Limited (KY) | 2003-11-19 | — | — | EP | claimed |
| WO-2002052949-A1 | AUTOINDUCER COMPOUNDS AND THEIR USES | GORMAR MARKETING LIMITED (KY) | 2002-07-11 | — | — | WO | claimed |
| EP-0912467-B1 | ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE | RHODIA CHIMIE SA (FR) | 2002-04-24 | — | — | EP | claimed |
| EP-4332086-B1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4556459-A1 | COMPOUND SERVING AS PRODUCTION INTERMEDIATE OF AMINO LIPID OR SALT THEREOF, AND METHOD FOR PRODUCING AMINO LIPID COMPOUND USING SAME | FUJIFILM Corporation (JP) | 2025-05-21 | — | — | EP | disclosed |
| US-20250145560-A1 | COMPOUND AS MANUFACTURING INTERMEDIATE OF AMINOLIPID OR SALT THEREOF AND METHOD FOR MANUFACTURING AMINOLIPID COMPOUND USING THE COMPOUND | FUJIFILM CORPORATION (JP) | 2025-05-08 | — | — | US | disclosed |
| CN-119487010-A | Compound as intermediate for producing amino lipid or salt thereof, and method for producing amino lipid compound using same | 富士胶片株式会社 | 2025-02-18 | — | — | CN | disclosed |
| US-20240124389-A1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-4332086-A1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | FUJIFILM Corporation (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024014430-A1 | COMPOUND SERVING AS PRODUCTION INTERMEDIATE OF AMINO LIPID OR SALT THEREOF, AND METHOD FOR PRODUCING AMINO LIPID COMPOUND USING SAME | 富士フイルム株式会社 | 2024-01-18 | — | — | WO | disclosed |
| EP-0295109-B2 | Process for preparing optically active alcohol | TAKASAGO PERFUMERY CO LTD (JP) | 1996-09-04 | — | — | EP | disclosed |
| US-5536453-A | COSMETICS | GIVAUDAN-ROURE CORPORATION, (US) | 1996-07-16 | — | — | US | disclosed |
| US-5481001-A | RADIATION RESISTANT COMPOSITIONS FOR COSMETICS | GIVAUDAN-ROURE CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0641792-A1 | 1,2-Dithiole derivatives and therapeutic agents containing them | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0532725-A1 | LIGHT SCREENING AGENT. | GIVAUDAN ROURE INT (CH) | 1993-03-24 | — | — | EP | disclosed |
| WO-1992017461-A1 | LIGHT SCREENING AGENT | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1992-10-15 | — | — | WO | disclosed |
| US-4933482-A | HYDROGENATION OF BETA-KETO ACID IN PRESENCE OF RUTHENIUM PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0295109-A1 | Process for preparing optically active alcohol | Takasago International Corporation (JP) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124389-A1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | NPC1L1, AUP1, LIPA | HAO1 2929/4885GAA 944/4885MGAM 4490/4885 |
| US-20250145560-A1 | COMPOUND AS MANUFACTURING INTERMEDIATE OF AMINOLIPID OR SALT THEREOF AND METHOD FOR MANUFACTURING AMINOLIPID COMPOUND USING THE COMPOUND | CETP, LCAT, LIPA | HAO1 1688/4885GAA 3214/4885MGAM 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.